If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Evolution ponders Panmure bid

Thu, 23rd Sep 2010 17:03
Broker and fund manager Evolution Group says that it is considering a bid for AIM-quoted broker Panmure Gordon. Evolution says that a Panmure offer is one of a number of options under consideration. No formal discussions have taken place with Panmure. Evolution says it is waiting to assess Panmure's interim results which will be announced on 29 September. Panmure points out that revenues are skewed towards the second half so the interim figures may not be that informative. The Panmure board argues that its 46.8% shareholder QInvest is supportive of its strategy.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Evgen agrees fresh licensing deal with Spanish institutions
18 Jan 2022

Evgen agrees fresh licensing deal with Spanish institutions

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consej...

Evgen signs agreement for Spanish institutions' sulfoaphane analogues
18 Jan 2022

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
7 Dec 2021

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

UK earnings, trading statements calendar - next 7 days
30 Nov 2021

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
10 Nov 2021

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
20 Sep 2021

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA
2 Sep 2021

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Evgen pleased with preclinical data on SFX-01
13 Jul 2021

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vit...